{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T11:42:09Z","timestamp":1784202129691,"version":"3.55.0"},"reference-count":10,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"50","license":[{"start":{"date-parts":[[2023,12,15]],"date-time":"2023-12-15T00:00:00Z","timestamp":1702598400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,12,15]]},"abstract":"<jats:sec>\n            <jats:title>Introduction:<\/jats:title>\n            <jats:p>We describe a rare case of a 54-year-old male diagnosed with both ulcerative colitis (UC) and hepatitis C virus (HCV), posing clinical challenges.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patient Concerns:<\/jats:title>\n            <jats:p>The patient showed worsened UC symptoms, leading to further evaluations.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Diagnosis:<\/jats:title>\n            <jats:p>Dual diagnosis of UC and HCV was confirmed through endoscopy and serological tests, ruling out other hepatic causes. Interventions: Treatment involved methylprednisolone for UC and sofosbuvir\/velpatasvir for HCV, with attention to drug interactions.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Outcomes:<\/jats:title>\n            <jats:p>Significant improvement was observed in both UC symptoms and HCV viral load post-treatment.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>This case underscores the need for nuanced treatment in managing concurrent UC and HCV, considering potential drug interactions and disease impacts.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000036629","type":"journal-article","created":{"date-parts":[[2023,12,15]],"date-time":"2023-12-15T21:02:23Z","timestamp":1702674143000},"page":"e36629","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Ulcerative colitis coexisting with hepatitis C: A rare occurrence"],"prefix":"10.1097","volume":"102","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-3737-513X","authenticated-orcid":false,"given":"Xiaoqiang","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, First Hospital of Quanzhou Affiliated to Fujian Medical University, Quanzhou, Fujian, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yisen","family":"Huan","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, First Hospital of Quanzhou Affiliated to Fujian Medical University, Quanzhou, Fujian, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yubin","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, First Hospital of Quanzhou Affiliated to Fujian Medical University, Quanzhou, Fujian, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingxuan","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, First Hospital of Quanzhou Affiliated to Fujian Medical University, Quanzhou, Fujian, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.gtc.2020.07.005","article-title":"Epidemiology and pathogenesis of ulcerative colitis.","volume":"49","author":"Du","year":"2020","journal-title":"Gastroenterol Clin North Am"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1016\/j.jhep.2020.08.018","article-title":"EASL recommendations on treatment of hepatitis C: final update of the series.","volume":"73","author":"Pawlotsky","year":"2020","journal-title":"J Hepatol"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"392","DOI":"10.5217\/ir.2022.00094","article-title":"Prevalence of hepatitis B virus and hepatitis C virus infection in patients with inflammatory bowel disease: a systematic review and meta-analysis.","volume":"21","author":"Giri","year":"2022","journal-title":"Intest Res"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1136\/gut.2010.208413","article-title":"Liver dysfunction related to hepatitis B and C in patients with inflammatory bowel disease treated with immunosuppressive therapy.","volume":"59","author":"Loras","year":"2010","journal-title":"Gut"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.jhep.2021.08.024","article-title":"Infliximab-induced liver injury: clinical phenotypes, autoimmunity and the role of corticosteroid treatment.","volume":"76","author":"Bj\u00f6rnsson","year":"2022","journal-title":"J Hepatol"},{"key":"R6-20250504","first-page":"1","article-title":"Tuberculosis and viral hepatitis infection in Eastern Europe, Asia, and Latin America: impact of tumor necrosis factor-\u03b1 inhibitors in clinical practice.","volume":"12","author":"Chen","year":"2018","journal-title":"Biologics"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"584","DOI":"10.2174\/1389557517666170913111930","article-title":"Recent advancement of direct-acting antiviral agents (DAAs) in hepatitis C therapy.","volume":"18","author":"Das","year":"2018","journal-title":"Mini Rev Med Chem"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.lfs.2018.12.004","article-title":"A comparative study of the efficiency of HCV NS3\/4A protease drugs against different HCV genotypes using in silico approaches.","volume":"217","author":"Ezat","year":"2019","journal-title":"Life Sci"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"867","DOI":"10.3389\/fphar.2017.00867","article-title":"Timing strategies of direct-acting antivirals and biologics administration in HCV-infected subjects with inflammatory bowel diseases.","volume":"8","author":"Imperatore","year":"2017","journal-title":"Front Pharmacol"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1111\/j.1440-1746.2011.06890.x","article-title":"Literature review in cases with exacerbation of ulcerative colitis induced by treatment with interferon and\/or ribavirin.","volume":"26","author":"Watanabe","year":"2011","journal-title":"J Gastroenterol Hepatol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000036629","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T01:13:55Z","timestamp":1746321235000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000036629"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,15]]},"references-count":10,"journal-issue":{"issue":"50","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000036629","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,15]]}}}